Daniel Drucker, MD, then a postdoctoral fellow in the Habener lab, characterized the enzymatic activity of GLP-1, while Jens Juul Holst, MD, at the University of Copehagen, simulatenously discovered GLP-1 regulated insulin secretion
Mol Cell Biol 34(4):606618 Nunn E, Jaiswal N, Gavin M, Uehara K, Stefkovich M, Drareni K, Calhoun R, Lee M, Holman CD, Baur JA (2024) Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism
Muscle preservation
[2] It should not be used with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping an MAOI